OmniAb, Inc. is a biotechnology company specializing in the discovery and optimization of therapeutic antibodies through its proprietary suite of discovery platforms. The company leverages transgenic animal models and in vitro display technologies to generate high-quality, fully human antibodies against a wide range of targets. Core platforms include OmniRat, OmniMouse and OmniChicken, which enable diverse epitope coverage, along with in vitro yeast and mammalian display systems for rapid affinity maturation and candidate refinement.
OmniAb’s services are designed to accelerate early-stage research and de-risk downstream development for biopharmaceutical partners. The company collaborates with global pharmaceutical and biotechnology firms to identify novel therapeutic antibody candidates in oncology, immunology, infectious disease and other areas of unmet medical need. By combining multiple discovery modalities under one roof, OmniAb can tailor campaigns to client requirements, from lead identification through lead optimization.
Founded in 2005 and headquartered in Vancouver, British Columbia, OmniAb operates research facilities in both Canada and the United States. Over the years, the company has built partnerships with leading drug developers, licensing its platforms and providing custom discovery programs. This collaborative approach enables clients to integrate OmniAb’s technologies into their internal pipelines or pursue joint development projects.
OmniAb is led by a management team with deep expertise in antibody engineering, translational research and biologics development. Under the leadership of President and CEO Colin McCracken, PhD, the company continues to expand its platform capabilities and service offerings, aiming to streamline the path from discovery to clinical candidate selection.
AI Generated. May Contain Errors.
